Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Study Overview
=================
Brief Summary
-----------------
Obese persons are known to have elevated levels of parathyroid hormone (PTH) and low levels of vitamin D. These hormones are important in regulation of the body's calcium stores and bone health. We would like to investigate these abnormalities and the accuracy of our current diagnostic tests by comparing results of standard assays for vitamin D and PTH to more specific tests, in obese subjects at baseline and as vitamin D is replaced. We will also compare two standard vitamin D replacement regimens to determine if one is more effective. This is a pilot study with two parts: Part 1 will compare levels of PTH and vitamin D using two different assays in obese subjects who have normal vitamin D and those who do not. We plan to enroll 20 subjects who have normal vitamin D levels and 40 subjects who have vitamin D insufficiency. All subjects will fill out questionnaires about the amount of calcium and vitamin D in their diet, and their recent sunlight exposure. We will ask for blood samples so that we can measure levels of calcium, vitamin D, albumin, creatinine, glucose, insulin and the different forms of PTH. Subjects who have vitamin D insufficiency will then be randomized to receive Vitamin D2 or Vitamin D3 in standard doses for eight weeks, in an open label trial. At four and eight weeks, these subjects will fill out the above questionnaires and have the blood tests repeated. For safety purposes, urine calcium will also be monitored.

Official Title
-----------------
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Conditions
-----------------
Obesity, Vitamin D Deficiency, Secondary Hyperparathyroidism

Intervention / Treatment
-----------------
* Drug: Ergocalciferol
* Drug: Cholecalciferol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obese subjects with body mass indices greater than 40 kg/m2 or 35 kg/m2 with other medical conditions secondary to obesity Willingness to take vitamin D supplements If baseline vitamin D level is >25 ng/ml subjects will be eligible for the control group If baseline vitamin D level is <25 ng/ml subjects will be eligible for one of the two vitamin D replacement groups Exclusion Criteria: Hypercalcemia Kidney disease Liver disease Malabsorption Prior diagnosis of bone disease Medical conditions requiring daily use of calcium, antacids, or medications known to affect bone metabolism or interact with vitamin D Hypersensitivity to any formulation of vitamin D

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ergocalciferol|nan|
|Drug: Cholecalciferol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vitamin D (25OHD):RIA and HPLC |  |  | 
| Parathyroid hormone (PTH):iPTH and 3rd generation RIA |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Parathyroid hormone carboxy terminal fragment levels PTH(7-84) |  |  | 
| Ratio of PTH (1-84) to PTH (7-84) |  |  | 
| Serum calcium level |  |  | 
| Urine calcium level |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D deficiency, Secondary hyperparathyroidism, Obesity